A detailed history of Virtus Investment Advisers, Inc. transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 19,112 shares of GLUE stock, worth $188,635. This represents 0.03% of its overall portfolio holdings.

Number of Shares
19,112
Previous 21,073 9.31%
Holding current value
$188,635
Previous $97,000 11.34%
% of portfolio
0.03%
Previous 0.03%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025

SELL
$3.7 - $5.33 $7,255 - $10,452
-1,961 Reduced 9.31%
19,112 $86,000
Q1 2025

May 14, 2025

BUY
$4.64 - $7.17 $97,778 - $151,093
21,073 New
21,073 $97,000
Q3 2022

Nov 14, 2022

BUY
$7.17 - $12.16 $90,614 - $153,678
12,638 New
12,638 $103,000

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $461M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Virtus Investment Advisers, Inc. Portfolio

Follow Virtus Investment Advisers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Investment Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Virtus Investment Advisers, Inc. with notifications on news.